Program
VH3810109
A development code.
In GlaxoSmithKline's pipeline, HIV broadly neutralizing antibody
. Its studies are mostly in HIV Infections, led by GlaxoSmithKline.
Furthest: phase 2, since Aug 9, 20233 company-led studies, 2 open or runningNext primary completion: Jan 22, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 32 open or running | phase 2since Aug 9, 2023 | Feb 16, 2022 | Jan 22, 2027phase 1 · NCT07053384 |
- Named in GlaxoSmithKline’s own pipeline as
VH3810109
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 16, 2022First study: phase 1 study in HIV InfectionsFirst studyNCT05291520 · 24 enrolled · United States
- Aug 9, 2023Phase 2 study in HIV InfectionsNCT05996471 · 185 enrolled · United States, Puerto Rico
- Jun 26, 2025Phase 1 study in HIV InfectionsNCT07053384 · 107 enrolled · United States, Belgium, Denmark and more
Ahead
- Jan 22, 2027Primary completion: phase 1 study in HIV InfectionsNCT07053384
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“HIV broadly neutralizing antibody”the company's pipeline, read by Claude · source
“This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase …”study summary, read by Claude · the study
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07053384HIV Infections · United States, Belgium, Denmark and more | 1 | Active, not recruiting | Jan 22, 2027 | 107 |
| NCT05996471HIV Infections · United States, Puerto Rico | 2 | Active, not recruiting | May 27, 2026 | 185 |
| NCT05291520HIV Infections · United States | 1 | Completed | Apr 10, 2023 | 24 |
How it is read
Names in the registry
- “VH3810109”, 3 entries
Codes read as this program: VH3810109.
Conditions, from the studies’ own filings
- HIV Infections, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.